中国医院用药评价与分析2025，Vol.25Issue(12)：1453-1456,4.DOI:10.14009/j.issn.1672-2124.2025.12.009
他汀类药物联合利伐沙班对脂代谢异常的心房颤动患者脂代谢水平、肝肾功能的影响及安全性分析
Effects and Safety of Statins Combined with Rivaroxaban on Lipid Metabolism and Hepatorenal Function in Patients with Atrial Fibrillation and Dyslipidemia
摘要
Abstract
OBJECTIVE:To probe into the effects of statins combined with rivaroxaban on lipid metabolism and hepatorenal function in patients with atrial fibrillation(AF)and dyslipidemia,and to analyze its safety.METHODS:A randomized,open-label and single-center prospective clinical cohort study was conducted,a total of 88 patients with AF and dyslipidemia admitted into the hospital from Aug.2022 to Aug.2024 were selected as the study subjects(observation group),another 40 AF inpatients with normal lipid levels(control group 1)and 40 inpatients with simple dyslipidemia(control group 2)during the same period were selected as control group.Both the observation group and control group 1 received conventional radiofrequency ablation therapy,and were given Rivaroxaban tablets after surgery,the observation group was additionally treated with either rosuvastatin or atorvastatin,while the control group 2 was given either rosuvastatin or atorvastatin,all patients were followed-up after 1 month of continuous treatment.The primary observation indicators were lipid metabolism indicators[total cholesterol(TC),triglycerides(TG),high-density lipoprotein(HDL),low-density lipoprotein(LDL)],the secondary observation indicators included inflammatory indicators[C-reactive protein(CRP),interleukin-6(IL-6),interleukin-10(IL-10)],oxidative stress indicators[endothelial nitric oxide synthase(eNOS),glutathione peroxidase(GSH-Px),angiotensin Ⅱ(Ang Ⅱ)],hepatorenal function indiocators[alanine aminotransferase(ALT),aspartate aminotransferase(AST),serum creatinine(SCr),blood urea nitrogen(BUN)]and clinical safety.RESULTS:After treatment,the TC,TG,and LDL levels were significantly lower and the HDL levels was significantly higher in the observation group and control group 2 than those before treatment,with statistically significant differences(P<0.05),but the comparison among different groups showed no statistically significant differences(P>0.05).After treatment,the serum CRP and IL-6 levels were significantly lower and the IL-10 levels was significantly higher in the observation group and control group 1 than those before treatment,with statistically significant differences(P<0.05),but the between-group comparisons showed no statistically significant differences(P>0.05).After treatment,the serum Ang Ⅱlevels were significantly lower,the eNOS and GSH-Px levels were significantly higher in the observation group and control 1 group than those before treatment,while the eNOS,GSH-Px and AngⅡ levels showed more significant improvements in the observation group than those in the control group 1,with statistically significant differences(P<0.05).After treatment,the hepatorenal function indicators(ALT,AST,SCr,and BUN)in the observation group and control group 1 showed no statistically significant differences compared with those before treatment(P>0.05),and the between-group comparisons showed no statistically significant differences(P>0.05).The incidences of adverse events in the observation group,control group 1 and control group 2 were 12.5%(11/88),12.5%(5/40)and 5.0%(2/40),respectively,the differences were not statistically significant(P>0.05).CONCLUSIONS:The combination of statins based on radiofrequency ablation and rivaroxaban can effectively improves lipid metabolism level in AF patients with dyslipidemia,which is helpful to reduce inflammatory level and oxidative stress level.It does not impair hepatorenal function of AF patients,which demonstrates good clinical safety.关键词
心房颤动/利伐沙班/脂代谢/瑞舒伐他汀/阿托伐他汀Key words
Atrial fibrillation/Rivaroxaban/Lipid metabolism/Rosuvastatin/Atorvastatin分类
医药卫生引用本文复制引用
Nuerbiya·ADILI,Abulimiti·JIAMALI,Miriban·YUSUFU,Nuerguli·TUOHETI..他汀类药物联合利伐沙班对脂代谢异常的心房颤动患者脂代谢水平、肝肾功能的影响及安全性分析[J].中国医院用药评价与分析,2025,25(12):1453-1456,4.基金项目
新疆维吾尔自治区自然科学基金资助项目(No.2022D01C309) （No.2022D01C309）
